🇺🇸 FDA
Patent

US 12233090

Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19

granted A61KA61K2039/505A61K2239/29

Quick answer

US patent 12233090 (Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19) held by The Regents of the University of California expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K2239/29, A61K2239/48, A61K35/17